What the research found
Denmark implemented stricter reimbursement criteria for GLP-1 receptor agonists in November 2024, requiring documented inability to use SGLT2 inhibitors and high cardiovascular risk before approving semaglutide for type 2 diabetes. Researchers tracked over 61,000 people on injectable semaglutide before and after this policy to understand real-world effects.
The policy had a modest initial dampening effect on semaglutide use, though prescriptions subsequently rebounded. Among those deemed eligible to continue, only 5.5% actually met the stated reimbursement criteria—the rest were already using SGLT2 inhibitors or didn't fit the high-risk profile. Of roughly 79,000 people filling prescriptions around the policy window, 28% stopped semaglutide within the observation period.
When people discontinued semaglutide, most didn't immediately switch to another diabetes medication. Those who did typically moved to SGLT2 inhibitors. Notably, one-third eventually restarted semaglutide after six months, suggesting the initial discontinuation may have been temporary. Blood glucose control (measured by HbA1c) deteriorated after stopping—rising an average of 7-8 mmol/mol in the first six months—and this worsening persisted even 18 months later, despite some partial improvement over time.
Why it matters for you
If you're using semaglutide as part of a metabolic health or body composition protocol, this research illustrates an important real-world risk: policy changes can interrupt access unpredictably. The Danish data suggests that once you stop, recovery of baseline glucose control takes months and may not fully occur. This matters if you're tracking HbA1c or fasting glucose as part of your biomarker monitoring—you should anticipate potential rises if access changes, and plan glycemic management accordingly.
The findings also highlight that SGLT2 inhibitors emerged as the primary fallback therapy when semaglutide became restricted. If you're optimizing with peptides, understanding alternative agents your clinician might propose is worth reviewing. The fact that many discontinuers didn't immediately adopt a replacement therapy suggests gaps in support when access shifts—something to flag with your healthcare provider if regulatory or insurance changes affect your protocol.
Finally, one-third of people restarting semaglutide months later indicates that initial discontinuation doesn't always reflect genuine long-term cessation. If your access is interrupted, reassessing eligibility or seeking reinstatement after a waiting period may be worth exploring depending on your jurisdiction.
Caveats
- Observational and registry-based: This tracked real prescribing and medical records, not a randomised trial, so causation and individual variation aren't fully characterized.
- Population-specific: Danish healthcare and reimbursement rules differ substantially from other countries; generalizability is limited.
- Incomplete follow-up on HbA1c: Only ~13,000 of the discontinuers had both pre- and post-discontinuation HbA1c measurements, and measurement timing varied (6–12 months post-stop).
- Policy-driven cohort: The discontinuation group was identified around the reimbursement change, not random; some may have stopped for clinical reasons independent of the policy.
- Short-to-medium term only: Data cover up to 18 months; longer-term glycemic trajectories and clinical outcomes are unknown.